ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.

Quote:

Search for Ticker

Free Membership

Search:

ALKS: Alkermes Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

ALKERMES INC (NASD)
ALKS	8.66	-0.25	(-2.81%)	Vol. 514,199	15:59 ET

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

General Information

ALKERMES INC

88 Sidney Street Cambridge, MA 02139-4234 Phone: 617-494-0171 Fax: 617-494-9263 Web: www.alkermes.com Email: financial@alkermes.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	March
Last Reported Quarter	09/30/09
Next EPS Date	02/04/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	8.91
52 Week High	13.16
52 Week Low	5.91
Beta	0.77
20 Day Moving Average	933,614.63
Target Price Consensus	10.21

% Price Change
4 Week	0.23
12 Week	-7.58
YTD	-18.68

% Price Change Relative to S&P 500
4 Week	-0.85
12 Week	-12.87
YTD	-32.70

Share Information
Shares Outstanding (millions)	94.39
Market Capitalization (millions)	817.43
Short Ratio	8.17
Last Split Date	05/15/2000

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.15
Current Year EPS Consensus Estimate	-0.50
Estimated Long-Term EPS Growth Rate	19.50
Next EPS Report Date	02/04/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	3.00
30 Days Ago	3.00
60 Days Ago	3.29
90 Days Ago	3.00

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	10.31
PEG Ratio	-

EPS Growth
vs. Previous Year	-550.00%
vs. Previous Quarter	18.18%

Sales Growth
vs. Previous Year	1.79%
vs. Previous Quarter:	1.39%

Price Ratios
Price/Book	1.94
Price/Cash Flow	5.81
Price / Sales	2.77

ROE
09/30/09	18.43
06/30/09	21.88
03/31/09	33.53

ROA
09/30/09	14.35
06/30/09	15.67
03/31/09	21.53

Current Ratio
09/30/09	6.36
06/30/09	7.10
03/31/09	5.45

Quick Ratio
09/30/09	6.03
06/30/09	6.71
03/31/09	5.16

Operating Margin
09/30/09	27.05
06/30/09	30.67
03/31/09	39.81

Net Margin
09/30/09	26.99
06/30/09	30.60
03/31/09	40.08

Pre-Tax Margin
09/30/09	26.99
06/30/09	30.60
03/31/09	40.08

Book Value
09/30/09	4.47
06/30/09	4.52
03/31/09	4.60

Inventory Turnover
09/30/09	2.23
06/30/09	2.15
03/31/09	2.36

Debt-to-Equity
09/30/09	0.09
06/30/09	0.10
03/31/09	0.12

Debt to Capital
09/30/09	8.23
06/30/09	9.35
03/31/09	10.35


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research